

# TABLE OF CONTENTS

## Abdominopelvic Cavity Infections and Antimicrobial Toxicities I

Abdominopelvic Cavity Infections and Antimicrobial Toxicities I Panel	3
---	---

## Clostridioides difficile Infection Epidemiology and Treatment

By Travis J. Carlson, Pharm.D., BCIDP

Introduction	7
Epidemiology	9
Clinical Guideline Updates for Management With Drug Therapy	11
First-line Therapies	14
Second-line Therapies	22
Conclusion	26
References	26
Self-Assessment Questions	34

## Clostridioides difficile Infection and the GI Microbiome

By Kelly R. Reveles, Pharm.D., Ph.D., BCPS; and Eric H. Young, Pharm.D.

Introduction	37
C. difficile Infection Pathogenesis	40
Microbiome-Mediated Risk Factors for Primary and Recurrent CDI	42
Microbiome-Targeted Therapies for CDI Primary and Secondary Prevention	44
Conclusion	50
References	50
Self-Assessment Questions	55

## Abdominopelvic Cavity Infections and Antimicrobial Toxicities II

Abdominopelvic Cavity Infections and Antimicrobial Toxicities II Panel	61
--	----

## Low-risk Community-Acquired Intra-abdominal Infections

By David A. Butler, Pharm.D., BCPS, AAHIVP; and Mark Biagi, Pharm.D., AAHIVP

Introduction	65
Pathophysiology and Classification of IAIs	66
Microbiology	71
General Management of IAIs	72
Assessing Risk of Treatment Failure and Death	72
Treatment of Uncomplicated IAI	77
Treatment of Lower Risk CA-clAI	82
Dosing and PK/PD	86

Definitive Antimicrobial Therapy for Lower Risk CA-clAI	87
Conclusion	91
References	91
Self-Assessment Questions	97

## High-risk Community- and Hospital-Acquired Intra-abdominal Infections

By Mark Biagi, Pharm.D., AAHIVP; and David A. Butler, Pharm.D., BCPS, AAHIVP

Introduction	101
Background	102
Microbiology	103
Treatment of High-Risk CA-clAI and HA-clAI	103
Dosing and Pharmacokinetics/Pharmacodynamics (PK/PD)	111
Definitive Treatment of Higher-Risk CA-clAI and HA-clAI	131
Conclusion	137
References	137
Self-Assessment Questions	145

## Abdominopelvic Cavity Infections and Antimicrobial Toxicities III

Abdominopelvic Cavity Infections and Antimicrobial Toxicities III Panel	153
---	-----

## Kidney Toxicity of Antibiotics

By Sean N. Avedissian, Pharm.D., MSc

Introduction	157
Frequency of Kidney Toxicity when Using Antibiotics	157
Antibiotics Known to Cause Kidney Toxicity	158
Mechanisms for Antibiotic-Induced Kidney Toxicity	161
Classifications for Acute Kidney Toxicity	162
Clinical Biomarkers Used to Identify Kidney Toxicity	164
Strategies to Mitigate Antibiotic-Induced Kidney Toxicity	167
Conclusion	167
References	167
Self-Assessment Questions	171

## Evaluating and Reporting Antimicrobial-Related Harms

By Nicholas Mercurio, Pharm.D., BCIDP; and Michael P. Veve, Pharm.D., MPH

Introduction	175
System-Based Antimicrobial-Associated Adverse Events	177
Leveraging Antibiotic-Related Harms in Antimicrobial Stewardship Practices	207
Conclusion	209

References .....	210
Self-Assessment Questions .....	217

**Abdominopelvic Cavity Infections and Antimicrobial Toxicities IV** ..... 223

Abdominopelvic Cavity Infections and Antimicrobial Toxicities IV Panel .....	225
--	-----

**Interactive Case: Spontaneous Bacterial Peritonitis**

*By Amelia K. Sofjan, Pharm.D., BCPS*

Interactive Case: Spontaneous Bacterial Peritonitis .....	229
Hyperlink to activity .....	229
Self-Assessment Questions .....	233

**Interactive Case: PK/PD Dosing Strategies in UTI**

*By Marguerite Monogue, Pharm.D., BCIDP*

Interactive Case: PK/PD Dosing Strategies in UTI .....	237
Hyperlink to activity .....	237
Self-Assessment Questions .....	242

**Interactive Case: Antimicrobial Prophylaxis for Post-Urologic Surgery UTI**

*By Jaclyn Cusumano, Pharm.D., BCIDP*

Interactive Case: Antimicrobial Prophylaxis for Post-urologic Surgery UTIs .....	248
Hyperlink to activity .....	248
Self-Assessment Questions .....	251